Shockwave Therapy for Erectile Dysfunction: Who May Benefit?

Low-intensity shockwave therapy (Li-SWT, also written LI-ESWT) is a non-surgical treatment studied mainly in vasculogenic erectile dysfunction, where impaired blood-vessel function contributes to difficulty achieving or maintaining an erection. It is not appropriate to describe shockwave therapy as a universal ED treatment or a proven cure. Current EAU guidance gives it a weak recommendation for selected men, including some with mild vasculogenic ED and some poor responders to PDE5-inhibitor medicines. Average improvements in trials are modest, and results vary because devices and treatment protocols are not standardised.

What is shockwave therapy for ED?

The treatment delivers low-intensity acoustic shockwaves to selected areas of the penis. The scientific rationale is related to tissue and vascular responses to mechanical energy, but the clinically important question is not whether a biological effect can be measured—it is whether erectile function improves enough to matter to the patient.

That distinction is important because many commercial claims go beyond what the evidence establishes.

Are all “shockwave” devices the same?

No. Clinical studies use different generators and different waveforms. Much of the positive ED literature involves focused low-intensity shockwaves. Radial pressure-wave devices deliver energy differently and should not automatically be treated as equivalent.

The EAU guideline specifically notes a randomised trial of radial wave therapy that did not show a significant benefit over placebo in erectile-function outcomes. A clinic or device using the word “shockwave” is therefore not enough to establish that the protocol matches the evidence base.

Relevant variables include:

• focused versus radial energy;
• energy flux density;
• number of pulses;
• anatomical treatment sites;
• number and frequency of sessions;
• device technology;
• whether PDE5 inhibitors or other treatments are used concurrently.

This heterogeneity is one reason there is no single internationally established session protocol.

How effective is Li-SWT for erectile dysfunction?

Systematic reviews and guideline assessments suggest that Li-SWT can produce a mild or modest average improvement in erectile-function scores in selected men with vasculogenic ED. The magnitude and durability of benefit vary considerably.

Some men report a clinically meaningful improvement; others do not. The available evidence does not justify guaranteeing that treatment will restore natural erections, eliminate the need for medication or prevent progression of vascular disease.

The strongest patient-selection signal is generally vasculogenic ED, particularly milder disease. Evidence is less persuasive when severe nerve damage, advanced structural tissue change or other non-vascular mechanisms dominate.

Who may be considered for shockwave therapy?

According to current EAU guidance, Li-SWT may be discussed with well-informed patients in selected situations such as:

• mild vasculogenic ED;
• men who prefer an alternative to oral vasoactive therapy or cannot use it;
• vasculogenic ED with poor response to PDE5 inhibitors.

“May be considered” is not the same as “is indicated for everyone in these groups”. The likely mechanism of ED still needs to be assessed.

When is benefit more uncertain?

Uncertainty is greater when ED is predominantly associated with:

• major neurological injury;
• severe post-surgical nerve damage;
• advanced, long-standing ED with little erectile tissue response;
• untreated endocrine disease;
• major psychological or relationship factors without evidence of vascular ED;
• active penile pain or another untreated penile disorder;
• expectations that shockwave therapy will replace an implant in end-stage ED.

Some men with severe ED or PDE5-inhibitor non-response have shown improvement in studies, but that does not mean results can be predicted for an individual patient.

What should be assessed before Li-SWT?

Shockwave therapy should not be the diagnostic test for ED. The cause should be assessed first.

The pattern of ED

History should clarify onset, severity, morning erections, sexual desire, ejaculation, previous treatment response and whether the problem is consistent or situational.

General health and medicines

Diabetes, hypertension, abnormal lipids, smoking, cardiovascular disease, pelvic surgery and current medicines can all change the probability of vasculogenic ED and treatment suitability.

Previous ED treatments

If a PDE5 inhibitor “did not work”, it is useful to check whether the medication was legitimate, prescribed appropriately and used correctly before labelling the patient a non-responder.

Examination and selected investigations

Blood pressure, metabolic and hormonal testing are part of the basic ED work-up. Penile duplex ultrasound may be useful in selected cases when a more detailed haemodynamic assessment would change treatment selection; it is not mandatory for every patient considering Li-SWT.

How is the treatment schedule planned?

There is no universally established regimen for ED. Published trials differ in total sessions, pulse counts, energy settings and treatment intervals. That variability should be stated openly rather than converted into one commercial “standard package”.

A treatment plan should identify the device type and the evidence supporting the protocol being proposed.

How many sessions are required?

There is no evidence-based single answer that applies to every device and patient. Research protocols commonly use multiple sessions over several weeks, but the numbers differ too much to present one schedule as universally correct.

If a provider gives a fixed number of sessions, the relevant question is whether that schedule is based on the particular device and published protocol being used.

Is anaesthesia needed?

Li-SWT is generally delivered as an outpatient treatment and is usually tolerated without anaesthesia in research and routine clinical use. Sensation varies, and discomfort can occur depending on device and energy settings.

The absence of anaesthesia does not mean that treatment is free of discomfort or adverse effects.

What adverse effects can occur?

Published ED studies generally report a low rate of short-term adverse events. Possible effects can include local discomfort, skin redness, bruising or transient sensitivity.

A low observed complication rate in trials does not prove that every device or protocol has the same safety profile. Equipment, energy settings, operator training and patient selection still matter.

Is the effect permanent?

No claim of permanent benefit is justified. The EAU guideline notes that improvement may become evident over the first months after treatment and can decline over time. Some studies report persistent effects at longer follow-up, but durability is inconsistent and the evidence base is heterogeneous.

A patient should therefore be counselled that further ED treatment may still be needed later.

Can Li-SWT be combined with ED medication?

Yes, combinations have been studied. Current EAU guidance allows Li-SWT with or without PDE5 inhibitors in selected patients. Some studies suggest combination treatment may improve outcomes in particular groups, but the evidence is not strong enough to prescribe one combination to every patient.

A patient should not stop prescribed ED medication simply because shockwave treatment has started. Changes should follow clinical review.

How is Li-SWT different from established ED treatments?

PDE5 inhibitors improve the erectile response while the medicine is active. Vacuum devices mechanically draw blood into the penis. Intracavernosal medicines directly induce smooth-muscle relaxation. Penile prostheses provide mechanical rigidity through an implanted device.

Li-SWT is different because it is intended to influence underlying penile vascular biology rather than produce an erection on demand. This mechanistic ambition is also why marketing claims can become exaggerated. Biological rationale should not be confused with proven disease reversal.

Is Li-SWT an alternative to a penile implant?

Not in every clinical situation. In mild vasculogenic ED, Li-SWT may be one of several non-surgical options. In severe ED caused by advanced nerve or tissue damage, a penile implant serves a fundamentally different purpose by providing mechanical rigidity.

Presenting shockwave therapy as an equivalent substitute for implant surgery in end-stage ED would misrepresent both treatments.

How should response be measured?

A useful follow-up looks at patient-relevant function, not only a device reading. It may include:

• change in erection rigidity;
• ability to achieve intercourse when that is the patient’s goal;
• validated erectile-function scores such as IIEF-EF or EHS;
• change in dependence on other treatments;
• adverse effects;
• whether the change is meaningful to the patient and partner.

Penile Doppler changes can be scientifically interesting, but improved blood-flow measurements do not automatically mean the patient has experienced a meaningful functional benefit.

Questions to ask before deciding on shockwave therapy

1. Is my ED likely to be vasculogenic?
2. What device is being used—focused shockwave or radial pressure wave?
3. Does the proposed protocol match published evidence for that device?
4. What degree of improvement is realistic in my clinical group?
5. What happens if there is no meaningful response?
6. Should my current ED medication continue during treatment?
7. How will response be measured?
8. Are other causes of ED being treated at the same time?

Medical information note

Li-SWT is a selective ED treatment with a weaker guideline recommendation than established first-line PDE5-inhibitor therapy. Evidence is most relevant to vasculogenic ED and is limited by heterogeneity in devices, protocols and outcomes. It should not be presented as a universal cure, a dependable replacement for medication, or an equivalent substitute for penile prosthesis surgery in severe ED.